|
Diabetic Nephropathy
|
0.100 |
Biomarker
|
disease |
BEFREE |
Absent or diminished pedal pulses and estimated GFR decline in patients with diabetic kidney disease.
|
31352861 |
2019 |
|
Diabetic Nephropathy
|
0.100 |
Biomarker
|
disease |
BEFREE |
In univariate time-dependent analyses, higher RPS DN class, increased IFTA, the presence of arteriolar hyalinosis and arteriosclerosis were associated with RRT initiation.In the fully adjusted model, the clinical characteristics associated with poor renal survival were longer duration of DM, lower eGFR, increased proteinuria and higher hematuria and the only pathologic lesions to remain significant were the GBM thickness and the IFTA.In conclusion, in this European cohort, the severity of glomerular lesions evaluated with the RPS DN classification had limited utility in predicting RRT initiation.
|
31277183 |
2019 |
|
Diabetic Nephropathy
|
0.100 |
Biomarker
|
disease |
BEFREE |
Although glomerular hypertension may be a mechanism of kidney injury in DKD, higher total GFR does not appear to be a risk factor for advanced DKD.
|
31123181 |
2019 |
|
Diabetic Nephropathy
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Diabetic kidney disease (DKD) is a heterogeneous disorder manifested as albuminuria and/or decreasing GFR.
|
29450720 |
2018 |
|
Diabetic Nephropathy
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
No relevant study has been performed in the Chinese population concerning SUDOSCAN in the screening of diabetic nephropathy (DN) in comparison with GFR.
|
28810595 |
2017 |
|
Diabetic Nephropathy
|
0.100 |
Biomarker
|
disease |
BEFREE |
The results highlight the importance of inflammation and endothelial dysfunction in diabetic nephropathy with reduced GFR.
|
27452162 |
2017 |
|
Diabetic Nephropathy
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The variability of several parameters influences the development of DKD, having a different impact on albuminuria development and on the decline in GFR.
|
28432733 |
2017 |
|
Diabetic Nephropathy
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Patients with DN and elevated TNF levels might benefit from tacrolimus treatment regarding maintaining GFR and reducing inflammation.
|
28060893 |
2017 |
|
Diabetic Nephropathy
|
0.100 |
Biomarker
|
disease |
BEFREE |
Thus, the LPAR antagonist BMS002 protects against GFR decline and attenuates development of DN through multiple mechanisms.
|
28739650 |
2017 |
|
Diabetic Nephropathy
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Finally, we observed a positive correlation between microdissected glomerular miR-26a expression levels and estimated GFR in patients with diabetic nephropathy.
|
26063197 |
2015 |
|
Diabetic Nephropathy
|
0.100 |
Biomarker
|
disease |
BEFREE |
Currently available rodent models exhibit characteristics of early diabetic nephropathy (DN) such as hyperfiltration, mesangial expansion, and albuminuria yet features of late DN (hypertension, GFR decline, tubulointerstitial fibrosis) are absent or require a significant time investment for full phenotype development.
|
25514595 |
2014 |
|
Diabetic Nephropathy
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Considering baseline GFR, age at enrolment and diabetes duration as confounders, Cox regression analysis identified 894GT genotype as a risk factor for DN progression (HR = 1.843 [95% CI 1.088 - 3.119], P = 0.023) and 894TT genotype as a risk factor for major cardiovascular event (HR = 2.515 [95% CI 1.060 - 5.965], P = 0.036).
|
24603156 |
2013 |
|
Diabetic Nephropathy
|
0.100 |
Biomarker
|
disease |
BEFREE |
NSA2 levels were the only variable that showed a significant difference between patients with albuminuria (DN-A) compared with non-albuminuric patients (DN-NA) and diabetic controls (p < 0.05), this increase being independent of all other variables, including GFR.
|
22095236 |
2012 |
|
Diabetic Nephropathy
|
0.100 |
Biomarker
|
disease |
BEFREE |
ADMA, SDMA and L-arginine/ADMA ratio standardised to GFR were identified as significant predictors of DN progression but not GFR decline using multivariate competing risk analysis.
|
23147199 |
2012 |
|
Diabetic Nephropathy
|
0.100 |
Biomarker
|
disease |
BEFREE |
We investigated the putative associations of genetic variants in CNDP1 and CNDP2 with diabetic nephropathy (defined either as micro- or macroalbuminuria) and estimated GFR in type 2 diabetic patients from Sweden.
|
21573905 |
2011 |
|
Diabetic Nephropathy
|
0.100 |
Biomarker
|
disease |
BEFREE |
Study comprised a total of 265 diabetics (type 1 or 2 or LADA) with normoalbuminuria (n = 94) or DN (n = 171). sRAGE (assessed by ELISA) was significantly higher in DN than normoalbuminuria subjects (P = 0.007) and positively correlated with age, S-urea, S-creatinine and albuminuria and AGEs (determined spectrofluorimetrically), negatively with GFR (all P < 0.05); however, multivariate regression revealed that GFR was the only independent variable associated with sRAGE (P = 0.047). sRAGE did not correspond with carrier state of risk-haplotype copies (RAGE2) (P > 0.05).
|
18615900 |
2008 |
|
Diabetic Nephropathy
|
0.100 |
Biomarker
|
disease |
BEFREE |
Diabetic nephropathy (DN) is a late diabetic complication that comprises progressively increasing albuminuria, declining GFR, and increased cardiovascular risk.
|
17151334 |
2007 |
|
Diabetic Nephropathy
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The impact of polymorphisms in the genes coding for angiotensinogen (M235T), ACE (ID), and angiotensin II type 1 receptor (A(1166)-->C) on decline in GFR and doubling of s-creatinine or development of ESRD in patients with type 1 diabetes and diabetic nephropathy (DN) was tested.
|
14569094 |
2003 |